GlassScriptPhysician profile
Fatoumata Diallo
NPI 1336763176
$1,420.84
in general payments reported to CMS, 2019-2025
14 companies · $17.24 in 2025
The $17.24 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $646 · 2023: $331 · 2024: $17.90 · 2025: $17.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $449.21 | 2021-2023 | Aristada, Aristada Initio |
| Abbvie INC. | $374.49 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.80 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $105.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $77.18 | 2022 | |
| Supernus Pharmaceuticals, INC. | $70.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $46.73 | 2022 | |
| Almatica Pharma LLC | $29.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.56 | 2021 | |
| Sunovion Pharmaceuticals INC. | $25.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.67 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.90 | 2024 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $17.24 | 2025 | Gvoke Hypopen |
| Indivior INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatoumata Diallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.